Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Colorectal Cancer Drug Development Pipeline Review, 2017 - Research and Markets

Research and Markets
Posted on: 12 Oct 17

The "Colorectal Cancer Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

The report, "Colorectal Cancer Drug Development Pipeline Review, 2017" provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Across all three indications, viral proteins, immune checkpoint proteins, kinases and DNA-related proteins are the most common targets, reflecting heavily both the pathophysiology and current treatment landscape associated with these diseases.

Scope

  • Which companies are the most active within the pipeline for colorectal cancer therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

  • 2cureX ApS
  • Biocon Ltd
  • Bionomics Ltd
  • Bionovis SA
  • Biotecnol Ltd
  • Biothera Pharmaceutical Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • EpiThany Inc
  • Etubics Corp
  • Exelixis Inc
  • Exicure Inc
  • F-star Biotechnology Ltd
  • Kura Oncology Inc
  • Laboratorio ELEA SACIF y A
  • Merrimack Pharmaceuticals Inc
  • Merus NV
  • Microlin Bio Inc
  • Millennium Pharmaceuticals Inc
  • MolMed SpA
  • Noxxon Pharma AG
  • NuCana BioMed Ltd
  • OBI Pharma Inc
  • Omnitura Therapeutics Inc
  • Peregrine Pharmaceuticals Inc
  • Pfizer Inc
  • PharmAbcine Inc
  • Rhizen Pharmaceuticals SA
  • Richter Gedeon Nyrt
  • Samumed LLC
  • Sanofi
  • Selvita SA
  • Siamab Therapeutics Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sigma-Tau SpA
  • Sigmoid Pharma Ltd
  • Sillajen Biotherapeutics
  • Simcere Pharmaceutical Group
  • Sorrento Therapeutics Inc
  • Steba Biotech SA
  • XuanZhu Pharma Co Ltd
  • Yabao Pharmaceutical Group Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/bk67tz/colorectal_cancer

View source version on businesswire.com: http://www.businesswire.com/news/home/20171012005847/en/

Business Wire
www.businesswire.com

Last updated on: 12/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.